Senomyx, Solae savory soy
This article was originally published in The Tan Sheet
Executive Summary
A partnership by soy protein supplier Solae and flavor technology developer Senomyx aims to improve soy protein's taste through the development of bitter blockers. Since April 2007, scientists from both firms have collaborated to determine the bitter components of soy protein and discovered new ingredients to modulate how taste receptors respond, the companies say Sept. 15. Under a licensing agreement, Solae will retain exclusive worldwide rights to use the soy protein flavor ingredients in all food and beverages, with Senomyx receiving royalties based on sales. San Diego-based Senomyx previously sought bitter-blocking agents for use in OTC pediatric products (1"The Tan Sheet" Jan. 16, 2006, p. 13). St. Louis-based Solae once pursued a qualified health claim linking soy protein to cancer prevention, but withdrew its petition in 2005 (2"The Tan Sheet" Oct. 31, 2005, In Brief)
You may also be interested in...
SupplySide West New Products In Brief
Frutarom sticks probiotic in functional gum: The Israeli flavor and ingredient firm offers an oral-cavity probiotic strain with reported immune-boosting properties, BLIS K12, as an ingredient for functional chewing gums. BLIS K12 promotes ear, nose and throat health and can also help prevent bad breath, Frutarom said in an Oct. 30 release. The company showcased the probiotic at the SupplySide West trade show Nov. 12 in Las Vegas in a 20-mg gum prototype made via a cold-press process by Tab Labs
Senomyx Seeks Alternatives To “Spoonful Of Sugar” To Make Meds Go Down
Senomyx expects to develop bitter flavor-blocking agents for use in pediatric OTC products in 2006, the biotechnology firm stated during a Jan. 12 presentation to investors
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.